Background
The carboxy-terminal fragment of osteogenic growth peptide [OGP (10) (11) (12) (13) (14) ] represents the bioactive form of the bone anabolic and hematopoietic stimulator agent OGP, retaining its effects [1] . The pentapeptide OGP (10) (11) (12) (13) (14) induces proliferation in fibroblast and osteoblast cell lines and enhances hematopoiesis both in vitro and in vivo [2] [3] [4] [5] [6] [7] . Previous studies demonstrated that OGP (10) (11) (12) (13) (14) reduces proliferation and induces differentiation of myeloblastic HL60 and megakaryoblastic TPO-primed M07-e cells (4, 8, 9) . The small G-protein RhoA and the tyrosine kinase Fyn belonging to the Src family (SFKs) are involved in these effects [8, 9] . It has been demonstrated that, in megakaryocytic cells, TPO activates Src kinases by its receptor Mpl [10] . Mpl display can be modulated by TPO binding and receptor internalization [11] . It has also been demonstrated that TGFb1, a member of the large superfamily of growth factors that control cell growth, proliferation, differentiation, and apoptosis in multiple lineages, is involved in megakaryocytic differentiation [12, 13] . Taking into account our previous study showing that OGP (10) (11) (12) (13) (14) reduces proliferation and induces M07-e differentiation through RhoA activation and Src inhibition [9] , in the present study we have gone deeper into this signal transduction pathway and investigated the possible involvement of TGFb1 and Mpl.
Material and Methods

Cell culture and culture conditions
Megakaryoblastic M07-e TPO responsive cell line (DSMZ: German Collection of Micro-organisms and Cell Cultures) was maintained in RPMI 1640 medium (Sigma, St. Louis, MO, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS-Gibco, Gaithersburg, MD, USA), 2 mM L-Glutamine (Sigma), 100 U/L penicillin-100 g/L streptomycin (Sigma), and 50 ng/mL rh TPO (Pepro-Tech EC Ltd, London, UK) at 37°C in a humidified atmosphere containing 5% CO 2 . For all experiments, cells were pre-cultured for 24 hours in IST (Sigma)-RPMI medium and then treated with OGP(10-14) (linear osteogenic growth peptide 10-14; Abiogen Pharma SpA, Pisa, Italy), PP2 SFK inhibitor (Calbiochem, La Jolla, CA, USA) and C3 Rho inhibitor (Upstate Biotechnology, Lake Placid, NY, USA) at 10 -11 M, 1 µM and 2 µg/ml, respectively, according to the conditions already reported in our previous paper [9] . PP2 SFK inhibitor was dissolved in DMSO and added to cell cultures 40 minutes before adding OGP (10) (11) (12) (13) (14) . DMSO was used at a concentration that does not interfere with M07-e cell proliferation [9] . Experiments were performed at 1, 72 and 144 hours on the basis of the previous results, showing in M07-e cells RhoA activation and signs of differentiation at 1h and 144h, respectively [9] .
All experiments were repeated at least 3 times. The significance of differences between experimental variables was determined using a parametric t-test.
Quantitative expression of activated RhoA
To measure activated RhoA, we used serum-free conditions to avoid artifacts from serum protein that activate RhoA [14] . According to RhoA G-LISA™ test instructions (Cytoskeleton, Denver, CO, USA), cells treated with OGP (10) (11) (12) (13) (14) and/or PP2 for 1 hour were lysed and snap frozen in liquid nitrogen. Then, cell lysates were thawed and the protein concentrations normalized to total protein amount. Cell lysates were added to the microplate containing the Rho-GTP-binding protein linked to the wells. After 30 minutes samples were washed twice and incubated with the antigen presenting buffer for 2 minutes and with the anti-RhoA primary antibody for 45 minutes. After 2 washes, samples were incubated with the secondary horse radish peroxidase conjugate (HRP) antibody for 45 minutes, and finally with HRP detection reagent for 15 minutes. The absorbance values were recorded at 490 nm using a Bio-Rad microplate reader (Hercules, CA, USA). For all experiments, positive (CTRL+) and negative (CTRL-) controls were used. In particular, CTRL+ and CTRL-consisted of constitutively active RhoA (RhoA-GTP) and lysis buffer, respectively.
Immunocytochemical analysis
Cells were plated on glass slides by centrifugation at 400 rpm for 5 minutes, air-dried and fixed with 1% formalin for 10 minutes at 4°C. For antigen retrieval, cytospins were exposed to 0.2% Triton X-100 solution (Sigma) for 10 minutes (for Mpl detection) or to microwaves for 3×5 minutes at 600 W in 10 mM sodium citrate (for TGFb1 and Src activated detection). Slides were then treated with 0.6% H 2 O 2 /cold methanol for 15 minutes, with normal swine serum (1:20; Sigma) for 20 minutes and with anti TGFb1 (sc-146; Santa Cruz Biotechnology; Santa Cruz, CA, USA), activated Src (Tyr 416; Santa Cruz Biotechnology) and c-Mpl (sc-15403, Santa Cruz Biotechnology) rabbit polyclonal antibodies diluted in 0.1% BSA/PBS overnight at 4°C. The detection protocol was carried out using biotinylated link antibodies and streptavidin-peroxidase complex (LSAB kit, Dakopatts, Glostrup, Denmark), and diaminobenzidine (DAB, Sigma) or 10% nickel-DAB enhanced (for c-Mpl detection) as chromogens for 5 minutes in the dark. After counterstaining by hematoxylin or nuclear fast red, samples were dehydrated, mounted with DPX mountant (Fluka, Buchs, Switzerland) and observed with a DMRB Leica microscope. Negative controls were obtained by incubating the specimens with 0.1% BSA-PBS, omitting the primary antibody. Results were evaluated either by optical observation on 50 cells minimum per sample, or by image analysis.
Image analysis system
A "Quantimet +" image analysis system was used to evaluate the reacting surfaces per cell and the degree of reactivity. Two series of 10 microscopic fields, the former from immunostained slides, the latter from negative controls, were frozen and captured. The gray levels of immunostained samples were compared with those of negative controls and the image analysis data were obtained according to conditions already reported by our group [15] . The final rate of immunoreactivity/cell was calculated by the product of the extension (percentage of positive cell surface) and the intensity (mean gray level of the reaction), on 50 cells per sample.
results
Expression of Mpl
Immunocytochemical evaluation of Mpl expression was performed on the samples treated with OGP (10) (11) (12) (13) (14) and/or PP2 
Expression of TGFb1
Intracellular TGFb1 immunocytochemical expression was performed on samples treated with OGP (10-14) for 72 and 144 hours, with or without PP2 or C3 inhibitors. TGFb1 factor was expressed on all the samples at the level of every cell, variously distributed in the cytoplasm. Image analysis performed on the 144-hour treated samples showed a higher immunoreactivity compared to 72-hour-treated samples. Image analysis data, summarised in Figure 1B 
Expression of activated RhoA
The results showed that in 1-hour OGP (10- 
Expression of activated Src
Expression of activated Src was evaluated by immunocytochemical analysis with an antibody that detects endogenous levels of Src only when they are phosphorylated at Tyr 416 . As we expected, control samples, treated with TPO, showed Src activated at both 1 and 72 hours, while PP2 and OGP (10) (11) (12) (13) (14) prevented this activation. The immunoreaction was present in the control cells only ( Figure 1D ). [10] [11] [12] [13] [14] promotes bone formation and hemopoiesis, while it reduces Mk-CFU growth of bone marrow-derived cells from patients affected by idiopathic myelofibrosis, and it reduces the proliferation of megakaryoblastic M07-e cells promoting their differentiation [4, 9] . Our group has previously demonstrated that RhoA and Src kinases are involved in the OGP(10-14)-induced differentiation of the megakaryoblastic M07-e cell line. In particular, we showed that PP2 reduces proliferation and induces differentiation as OGP (10) (11) (12) (13) (14) , demonstrating a co-operative action of these agents [9] . Here, we have demonstrated by quantitative data that both OGP (10) (11) (12) (13) (14) and PP2 activate RhoA, and that their association activates a larger amount of RhoA compared to those activated by the 2 molecules separately. Moreover, we showed that OGP (10) (11) (12) (13) (14) (10) (11) (12) (13) (14) only in TPO-dependent, but not in GM-CSF-dependent M07-e cells [9] . TGFb1 could be the key molecule that links RhoA to Mpl; in fact, TGFb1 is able to down-modulate the Mpl receptor on hematopoietic stem/progenitors [17] and to antagonize the proliferative effect of TPO on the M07-e cell line [13] . Here, we have found that in these cells OGP (10) (11) (12) (13) (14) modulates TGFb1 expression, inducing an increase through RhoA, since it is prevented by the C3 treatment. Also, PP2 enhances TGFb1 expression, showing again the same behavior of OGP (10) (11) (12) (13) (14) and causing an additive effect when associated with it. PP2 could induce a TGFb1 increase, preventing the inactivation of RhoA due to SFK activation.
conclusions
In a previous study we have demonstrated that OGP (10) (11) (12) (13) (14) and PP2 reduce proliferation and induce differentiation of TPO-primed M07-e cells through RhoA/SFK signalling pathways. In the present study we found again that PP2 and OGP (10) (11) (12) (13) (14) show the same effects, increasing TGFb1 expression and RhoA activation, and inhibiting Src activation. Thus, on the basis of previous [9] and present results, we suggest an OGP(10-14) differentiation signaling pathway model (Figure 2) , showing that OGP(10-14) induces M07-e cell differentiation preventing SFK activation caused by activated RhoA. In this pathway activated RhoA induces a TGFb1 increase that down-modulates Mpl [17] , preventing SFK activation.
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